secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0001737287-23-000079
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Allogene appoints Geoffrey Parker as CFO effective Oct 16, 2023
---------------------------------------------------------------

- Geoffrey Parker named EVP, CFO, Principal Financial & Accounting Officer, effective Oct 16, 2023.
- Previously COO/CFO at Tricida, CFO at Anacor (sold to Pfizer for $5.2B), MD at Goldman Sachs.
- Receives $490k base salary, 45% target bonus pro-rated for 2023, option for 950k shares, 400k RSUs.
- Also eligible for performance RSUs of 390k shares tied to $18 stock price or first FDA approval by 2028.
- Severance under CIC Plan: 18 months salary on change-in-control termination; 12 months on involuntary termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000079/0001737287-23-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000079/allo-20231016.htm
  HTML page:      https://secwatch.observer/filing/0001737287-23-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer